In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Vical Inc (NASDAQ: VICL), with a price target of $3.50. The company’s shares closed yesterday at $1.33, close to its 52-week low of $1.02.
Selvaraju said:
“Valuation methodology, risks and uncertainties. We employ a discounted cash flow (DCF)-based approach to valuing Vical, which drives a total risk-adjusted net present value (NPV) of roughly $100M, or a price per share of $3.50, assuming 29M fully-diluted shares outstanding at end-3Q19.”
According to TipRanks.com, Selvaraju has currently no stars on a ranking scale of 0-5 stars, with an average return of -2.8% and a 33.9% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Vical Inc with a $3.50 average price target.
See today’s analyst top recommended stocks >>
Based on Vical Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $4.87 million. In comparison, last year the company had a GAAP net loss of $3.32 million.
Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VICL in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. It has active development programs which comprises of ongoing phase 2 trial of HSV-2 therapeutic vaccine, VCL-HB01, to treat patients with symptomatic genital herpes infection; ongoing phase 2 trial of novel antifungal VL-2397, for the treatment of patients with invasive aspergillosis; and early stage development program of a novel treatment for chronic hepatitis B virus (CHB) infection based on its DNA and lipid-delivery technologies. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA.
Read More on VICL:
